In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...

Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...

Emergen Research Logo The DNA Testing market is expected to grow from an estimated USD 12.51 billion in 2024 to USD 81.82 billion in 2033, ...

The gene panel market is expected to grow at 20.02 % CAGR from 2023 to 2030. It is expected to reach above USD 13.2 billion by 2030 from USD 3.02 billion in 2023. List of the Top Key Players of the ...

When it comes to hair loss, there are as many myths about it as there are treatments for it. An expert broke down common ...